These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32826086)

  • 1. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
    Baldallo C; León Román JC; Serón D; Agraz I; Solans R; Ramos N; Soler MJ
    Nefrologia (Engl Ed); 2021; 41(3):354-356. PubMed ID: 32826086
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 in a patient with hypocomplementemic urticarial syndrome and MPO-ANCA vasculitis on hemodialysis treated with omalizumab.
    Baldallo C; León Román JC; Seron D; Agraz I; Solans R; Ramos N; Soler MJ
    Nefrologia (Engl Ed); 2021; 41(3):354-355. PubMed ID: 36166252
    [No Abstract]   [Full Text] [Related]  

  • 3. A case report of hypocomplementemic urticarial vasculitis presenting with membranoproliferative glomerulonephritis.
    Vallianou K; Skalioti C; Liapis G; Boletis JN; Marinaki S
    BMC Nephrol; 2020 Aug; 21(1):351. PubMed ID: 32811472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 infection under omalizumab therapy for chronic spontaneous urticaria: three cases.
    Ayhan E; Öztürk M; An İ; Bekçİbaşi M
    Int J Dermatol; 2021 Feb; 60(2):253-254. PubMed ID: 33332576
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria.
    Di Leo E; Calogiuri G; Macchia L; Nettis E
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):300-302. PubMed ID: 29802908
    [No Abstract]   [Full Text] [Related]  

  • 6. Successful treatment of urticarial vasculitis with omalizumab in children: a case series.
    Wang S; Fu L; Xiang X; Zhang B; Ma L; Xing H
    Clin Exp Dermatol; 2023 Sep; 48(10):1145-1148. PubMed ID: 37227921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omalizumab does not improve skin lesions in a patient with hypocomplementemic urticarial vasculitis syndrome.
    Aurich S; Simon JC; Treudler R
    J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):e395-e397. PubMed ID: 28273376
    [No Abstract]   [Full Text] [Related]  

  • 8. A Case of Hypocomplementemic Urticarial Vasculitis Syndrome Successfully Treated With Omalizumab.
    Nucera E; Basta F; Buonomo A; Mezzacappa S; Margiotta DP; Antonelli Incalzi R; Schiavino D
    J Investig Allergol Clin Immunol; 2017; 27(6):382-384. PubMed ID: 29199964
    [No Abstract]   [Full Text] [Related]  

  • 9. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
    Skander D; Allenova A; Maurer M; Kolkhir P
    Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of omalizumab in chronic spontaneous urticaria associated with chronic inducible urticaria.
    Dortas Junior S; Azizi G; Valle S
    Ann Allergy Asthma Immunol; 2020 Oct; 125(4):486-487. PubMed ID: 32544531
    [No Abstract]   [Full Text] [Related]  

  • 11. Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Hayama K; Fujita H; Asai-Sato M; Kawana K; Terui T
    Eur J Dermatol; 2021 Feb; 31(1):100-101. PubMed ID: 33459258
    [No Abstract]   [Full Text] [Related]  

  • 12. H1-Antihistamines May No Longer Be Necessary for Patients With Refractory Chronic Spontaneous Urticaria After Initiation of Omalizumab.
    Ensina LF; Arruda LK; Campos RA; Criado RF; Rodrigues Valle S; Melo JM; Oliveira JC; Dortas JS; Cusato-Ensina AP; Camelo-Nunes IC; Agondi RC
    J Investig Allergol Clin Immunol; 2020 Apr; 30(2):145-147. PubMed ID: 31762438
    [No Abstract]   [Full Text] [Related]  

  • 13. Crescentic membranoproliferative glomerulonephritis and hypocomplementemic urticarial vasculitis.
    Enríquez R; Sirvent AE; Amorós F; Pérez M; Matarredona J; Reyes A
    J Nephrol; 2005; 18(3):318-22. PubMed ID: 16013022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Belbezier A; Boccon-Gibod I; Bouillet L
    Eur J Dermatol; 2021 Feb; 31(1):86-87. PubMed ID: 33772528
    [No Abstract]   [Full Text] [Related]  

  • 15. Omalizumab for chronic urticaria in children younger than 12 years.
    Al-Shaikhly T; Rosenthal JA; Ayars AG; Petroni DH
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):208-210.e2. PubMed ID: 31082483
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of four types of chronic urticaria with anti-IgE omalizumab in the same patient.
    Nettis E; Di Leo E; Calogiuri G; Foti C; Macchia L
    Ann Allergy Asthma Immunol; 2019 Mar; 122(3):336-337. PubMed ID: 30529714
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of omalizumab on patient-reported outcomes in chronic idiopathic urticaria: Results from a randomized study (XTEND-CIU).
    Casale TB; Murphy TR; Holden M; Rajput Y; Yoo B; Bernstein JA
    J Allergy Clin Immunol Pract; 2019; 7(7):2487-2490.e1. PubMed ID: 31034999
    [No Abstract]   [Full Text] [Related]  

  • 18. Safely use of omalizumab during SARS-CoV-2 infection in patients with chronic spontaneous urticaria.
    Özdemir Ö; Dikici Ü
    J Cosmet Dermatol; 2023 Jan; 22(1):26-27. PubMed ID: 36448319
    [No Abstract]   [Full Text] [Related]  

  • 19. Characteristics of patients with chronic spontaneous urticaria showing early and complete responses to omalizumab.
    Cho YT; Fu KT; Yang CW; Chu CY
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):394-395. PubMed ID: 34102302
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study.
    Abduelmula A; Georgakopoulos JR; Mufti A; Devani AR; Gooderham MJ; Hong CH; Jain V; Lansang P; Vender R; Prajapati VH; Yeung J
    J Cutan Med Surg; 2022; 26(3):319-320. PubMed ID: 34587789
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.